GSK Advances Wave’s siRNA Program, Triggers $12M Milestone
Event summary
- GSK selected a hepatology siRNA program from Wave’s collaboration for further development.
- Wave receives a $12M milestone payment, with up to $330–375M in additional milestones per program.
- Three additional collaboration programs are advancing toward candidate selection.
- Wave’s SpiNA siRNA technology is highlighted for superior pharmacology and potency.
The big picture
This deal underscores the growing strategic importance of RNA-based therapeutics in drug development, particularly in hepatology. Wave’s ability to leverage its PRISM platform and human genetic insights positions it as a key player in the RNA medicines space, with GSK’s validation potentially attracting further partnerships. The financial upside, including milestone payments and royalties, highlights the high-stakes nature of biotech collaborations.
What we're watching
- Pipeline Momentum
- Whether Wave can sustain progress with its three additional collaboration programs.
- Technology Validation
- How GSK’s adoption of Wave’s SpiNA siRNA technology will impact competitive positioning.
- Financial Upside
- The pace at which Wave can convert collaboration milestones into revenue.
Related topics
